Core Energy
Commercial- Indications
- Fatigue, Mitochondrial dysfunction
Company intelligence / Profile preview
K-PAX Pharmaceuticals, Inc.
Mill Valley, California, United Stateskpaxhealth.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Commercial
01
Overview
Clinical trials showed KPAX002 (methylphenidate plus K-PAX Immune) improved overall Chronic Fatigue Syndrome symptoms by 34% at 12 weeks and reduced Gulf War Illness symptoms by 25% at 12 weeks. The micronutrient formula also improved CD4 cell count in HIV-infected patients taking HAART[10].
- Therapeutic areas
- OtherImmunologyInfectious Diseases
- Modalities
- Micronutrient formulasCombination therapies (supplements with pharmaceuticals)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Previously partnered with Bristol-Myers Squibb for research funding[5]
Beyond the preview
Go deeper on K-PAX Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on K-PAX Pharmaceuticals, Inc..